Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rentokil
RTO
|
+$514M |
| 2 |
APLS
Apellis Pharmaceuticals
APLS
|
+$210M |
| 3 |
TFI International
TFII
|
+$145M |
| 4 |
Ambev
ABEV
|
+$142M |
| 5 |
Vanguard S&P 500 ETF
VOO
|
+$133M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$8.38B |
| 2 |
Apple
AAPL
|
+$5.7B |
| 3 |
Amazon
AMZN
|
+$3.72B |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$3.64B |
| 5 |
Mastercard
MA
|
+$3.47B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.11% |
| 2 | Healthcare | 21.42% |
| 3 | Financials | 11.42% |
| 4 | Industrials | 10.73% |
| 5 | Consumer Discretionary | 10.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2401
Clover Health Investments
CLOV
$2.29B
| $59.2K | ﹤0.01% |
63,843
-63,839
| -50% | -$85.2K |
|
2402
NextDecade
NEXT
$1.78B
| $58.5K | ﹤0.01% |
+11,886
| New | +$68.3K |
|
2403
Arlo Technologies
ARLO
$1.57B
| $58K | ﹤0.01% |
16,504
-16,504
| -50% | -$67.9K |
|
|
WE
2404
DELISTED
WeWork Inc.
WE
| $56.4K | ﹤0.01% |
982
-982
| -50% | -$92K |
|
2405
Purple Innovation
PRPL
$31.6M
| $56.2K | ﹤0.01% |
470
-490
| -51% | -$53.6K |
|
2406
Solid Power
SLDP
$463M
| $56.1K | ﹤0.01% |
22,031
-22,033
| -50% | -$94.2K |
|
2407
Codexis
CDXS
$159M
| $55K | ﹤0.01% |
11,804
-11,804
| -50% | -$64.7K |
|
|
CNSL
2408
DELISTED
Consolidated Communications Holdings, Inc.
CNSL
| $51.8K | ﹤0.01% |
14,500
-14,500
| -50% | -$64.3K |
|
2409
Ribbon Communications
RBBN
$373M
| $51.8K | ﹤0.01% |
18,595
-18,595
| -50% | -$48.2K |
|
2410
Ocugen
OCGN
$427M
| $50.1K | ﹤0.01% |
38,363
-38,363
| -50% | -$59.8K |
|
2411
Butterfly Network
BFLY
$2.14B
| $50K | ﹤0.01% |
20,275
-20,277
| -50% | -$72.8K |
|
2412
Smartbird Inc
BIRD
$20.3M
| $48.6K | ﹤0.01% |
1,007
-1,006
| -50% | -$59K |
|
|
AMRS
2413
DELISTED
Amyris Inc.
AMRS
| $48.6K | ﹤0.01% |
31,835
-31,843
| -50% | -$71.1K |
|
|
SRNE
2414
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $48.3K | ﹤0.01% |
54,766
-54,760
| -50% | -$72.6K |
|
2415
Atara Biotherapeutics
ATRA
$73.6M
| $47.5K | ﹤0.01% |
582
-583
| -50% | -$60.8K |
|
2416
SmartRent
SMRT
$197M
| $47.2K | ﹤0.01% |
19,450
-19,448
| -50% | -$48.1K |
|
2417
Nuvation Bio
NUVB
$2.33B
| $46.7K | ﹤0.01% |
24,375
-24,373
| -50% | -$49.3K |
|
|
MMAT
2418
DELISTED
Meta Materials Inc. Common Stock
MMAT
| $45.8K | ﹤0.01% |
390
-390
| -50% | -$51.6K |
|
2419
Hyliion Holdings
HYLN
$646M
| $44.9K | ﹤0.01% |
19,220
-19,224
| -50% | -$52.2K |
|
2420
Heron Therapeutics
HRTX
$94.1M
| $44.3K | ﹤0.01% |
17,739
-17,735
| -50% | -$57.1K |
|
2421
Microvast
MVST
$267M
| $44.1K | ﹤0.01% |
28,940
-28,938
| -50% | -$59K |
|
|
ILPT
2422
Industrial Logistics Properties Trust
ILPT
$565M
| $43.4K | ﹤0.01% |
13,261
-13,261
| -50% | -$55.2K |
|
|
BBBY
2423
DELISTED
Bed Bath & Beyond Inc
BBBY
| $43.3K | ﹤0.01% |
17,276
-17,274
| -50% | -$67.8K |
|
|
CMAX
2424
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $41.7K | ﹤0.01% |
+380
| New | +$56.8K |
|
2425
Karyopharm Therapeutics
KPTI
$159M
| $41.5K | ﹤0.01% |
813
-813
| -50% | -$56.4K |
|
Similar funds
Janus Henderson Group's Q4 2022 Portfolio in Review
As of Q4 2022, Janus Henderson Group held 2,666 positions worth $140B, down 48% from $267B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Janus Henderson Group withdrew a net $148B in Q4 2022, closing 210 positions and reducing 1,907 holdings. Its most notable exit was Terminix Global Holdings, Inc., an estimated $901M position sold in full.
By sector, the portfolio is most concentrated in Technology at 28% of assets, down from 30% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Janus Henderson Group opened a new position in Rentokil worth $510M.
- Janus Henderson Group's largest Q4 2022 buy was Rentokil: 16,564,405 shares worth $510M.
- Janus Henderson Group added most to Apellis Pharmaceuticals in Q4 2022, an estimated $210M increase.
- Janus Henderson Group's biggest Q4 2022 reduction was Microsoft, cutting an estimated $8.38B.
- Janus Henderson Group fully exited Terminix Global Holdings, Inc. in Q4 2022, selling an estimated $901M.
- Janus Henderson Group's ten largest holdings make up 22% of its $140B portfolio in Q4 2022.
- Janus Henderson Group opened 131 new positions and closed 210 in Q4 2022.
- Janus Henderson Group's portfolio value fell 48% quarter-over-quarter to $140B.
Based on Janus Henderson Group's 13F filing for Q4 2022, filed 14 Feb 2023.